A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy-Reference-Cited by-同舟云学术

A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy

Published:2009-11 Issue:11 Volume:20 Page:1874-1880
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Segawa Y.,Aogi K.,Inoue K.,Sano M.,Sekine I.,Tokuda Y.,Isobe H.,Ogura T.,Tsuboi M.,Atagi S.

Funder

Taiho Pharmaceutical Co., Ltd

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/11/1874/474013/mdp243.pdf

Reference23 articles.

1. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment;Bloechl-Daum;J Clin Oncol,2006

2. The impact of cytotoxic chemotherapy—perspectives from patients, specialists and nurses;Cooper;Eur J Cancer,1992

3. Adverse effects of treatment: nausea and vomiting;Berger,1997

4. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy;The Italian Group for Antiemetic Research;N Engl J Med,2000

5. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis;Frontiers in Oncology;2024-07-26

2. Efficacy of Olanzapine, Netupitant, and Palonosetron in Controlling Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy in Patients with Breast Cancer (OLNEPA);2023-04-21

3. Effects of Palonosetron on Nausea and Vomiting Induced by Multiple-Day Chemotherapy: A Retrospective Study;Biological and Pharmaceutical Bulletin;2021-04-01

4. Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study;Supportive Care in Cancer;2021-01-29

5. A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide;Cancer Medicine;2020-03-13